CCND1 and acral lentiginous melanoma: Another study reported that CDK4 copy number gain was negatively correlated with anti-PD1 response in all subtypes of advanced melanoma and CCND1 copy number gain was associated with a lack of response to anti-PD-1 therapy in advanced acral melanoma (20).